TechGowell

TechGowell is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of RNA interference (RNAi) therapeutics. The company leverages its proprietary delivery platforms, including advanced Lipid Nanoparticles (LNP) and GalNAc conjugation technologies, to target chronic diseases such as Hepatitis B (HBV), cardiovascular conditions, and metabolic disorders. TechGowell's lead programs include siRNA candidates for HBV and hyperlipidemia, aiming to provide long-acting and highly specific treatment options. The firm is positioned as a key player in the emerging Chinese RNAi landscape, focusing on high-prevalence indications with significant unmet medical needs.